TSM
Taiwan Semiconductor ManufacturClose $392.61EOD onlyThis page reflects TSM options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.
Historical consensus-supported lens with full content, report chain context, and metric rail.
You are viewing an older report from April 2, 2026. A newer directional report is available for April 6, 2026.
View latest reportOutlook
Neutral-to-bullish with a pinning magnet to $338-$340. Confidence: 8/10. Spot is now at max pain, GEX remains positive, and net premium is slightly bullish. The regime is stable, but mixed flow and high IV introduce noise.
Conflicts: Mixed flow (P/C vol 1.59 bearish, P/C OI 1.27), elevated IV (48.6%) adds premium-selling edge but also tail risk.
Regime Classification
Price Range Forecast
Key Levels
Dealer Positioning (GEX/DEX)
GEX: $+5.9M
DEX: +44.6M shares
Gamma flip: ~$330 (Approx — based on put OI concentration of 19,431)
NTM gamma: Gamma flip ~$330. Dealers are long gamma here, hedging to suppress volatility. A move below $330 accelerates selling; a move above $340 reduces pinning pressure.
IV Analysis
IV vs VIX: IV 48.6% is elevated — selling premium has edge in a pinning regime.
Term structure: Humped — 4/17 IV 48.7% > 4/10 IV 40.9%, pricing in 4/16 earnings. Steep drop to ~45% by May.
Skew: ~7.8 vol-point differential between 4/17 (48.7%) and 6/18 (45.4%) — supports selling near-term, buying longer-dated vol (reverse calendar).
Flow Analysis
Net premium: +$821K bullish; P/C vol 1.59 (put dominance), P/C OI 1.27 (put-heavy).
Directional prints: $280P 10/16 vol 10,020 vs OI 966 (10.4x) at 46.1% IV — large, fresh OI, likely bought puts for long-dated hedge or sold for premium; selling is more consistent with elevated IV and pinning. $335C 4/24 vol 1,142 vs OI 392 (2.9x) at 48.3% IV — near-term call buying targeting just below spot; could be bought for upside or sold against a position.
Unusual: $120P 5/15 vol 873 at 146.1% IV — extreme tail-risk hedging or very expensive premium selling; likely a low-probability lottery ticket.
Risks & Catalysts
Strategy Viability
| Strategy | Edge | Best Setup | Primary Risk |
|---|---|---|---|
| Long stock | Moderate | Entry on dip to $330 (gamma flip), target $340-$350. | Time to pin resolution; break below $330. |
| Short stock | Weak | Avoid; opposes GEX, max pain, and net premium bias. | Squeeze to $340-$350. |
| Covered call | Moderate-Strong | If long, sell $340C 4/17 for ~$5.00 credit (at max pain, high IV). | Upside capped at key resistance; earnings vol crush. |
| Cash-secured put / put spread | Moderate-Strong | Sell $330/$325 put spread 4/17 for credit (~$1.50). Strike at gamma flip and EM low. | Break below $322.5 (nearest valid strike to 1w EM low). |
| Long calls | Moderate | Buy $340C 4/17, sell $350C 4/17 for debit call spread (~$3.00). Targets max pain grind. | Time decay in elevated IV; pin holds range. |
| Long puts / bear put spread | Weak | Avoid; regime opposes. | Costly fade of pin and flow. |
| Iron condor | Moderate-Strong | Sell $330/$325P x $350/$355C 4/17. Wings at 1w EM bounds (using $322.5/$355). | Earnings vol crush after 4/17 expiry is a non-issue for this expiration. |
| Calendar/diagonal | Moderate-Strong | Sell $340C 4/17 (IV 48.7%), buy $340C 6/18 (IV 45.4%) for a credit reverse calendar. Bet on IV crush post-earnings. | Spot runs past $340 before earnings. |
| PMCC / LEAPS diagonal | Moderate | Buy $300C Jan 2027 (~$45), sell $340C 4/17 against it for ~$5.00. Finance long-dated bullish view with near-term IV. | Short call tested if pin runs quickly to $340. |
Top Plays
Watchlist Triggers
Tactical Summary
Each report translates the same market-close options snapshot into a specific lens such as directional bias, premium-selling posture, flow quality, or earnings setup.
Reports are most useful for narrowing the playbook, surfacing entry and risk context, and deciding which raw data page to inspect next.
These are interpretation layers, not execution guarantees. Validate the setup against chain liquidity, expected move, and exposure before sizing risk.